UniProt ID | UBQL2_HUMAN | |
---|---|---|
UniProt AC | Q9UHD9 | |
Protein Name | Ubiquilin-2 | |
Gene Name | UBQLN2 | |
Organism | Homo sapiens (Human). | |
Sequence Length | 624 | |
Subcellular Localization | Cytoplasm . Nucleus . Membrane . Cytoplasmic vesicle, autophagosome . Colocalizes with a subset of proteasomes, namely those that are cytoskeleton associated or free in the cytosol. Associated with fibers in mitotic cells. | |
Protein Description | Plays an important role in the regulation of different protein degradation mechanisms and pathways including ubiquitin-proteasome system (UPS), autophagy and the endoplasmic reticulum-associated protein degradation (ERAD) pathway. Mediates the proteasomal targeting of misfolded or accumulated proteins for degradation by binding (via UBA domain) to their polyubiquitin chains and by interacting (via ubiquitin-like domain) with the subunits of the proteasome. [PubMed: 10983987 Plays a role in the ERAD pathway via its interaction with ER-localized proteins FAF2/UBXD8 and HERPUD1 and may form a link between the polyubiquitinated ERAD substrates and the proteasome] | |
Protein Sequence | MAENGESSGPPRPSRGPAAAQGSAAAPAEPKIIKVTVKTPKEKEEFAVPENSSVQQFKEAISKRFKSQTDQLVLIFAGKILKDQDTLIQHGIHDGLTVHLVIKSQNRPQGQSTQPSNAAGTNTTSASTPRSNSTPISTNSNPFGLGSLGGLAGLSSLGLSSTNFSELQSQMQQQLMASPEMMIQIMENPFVQSMLSNPDLMRQLIMANPQMQQLIQRNPEISHLLNNPDIMRQTLEIARNPAMMQEMMRNQDLALSNLESIPGGYNALRRMYTDIQEPMLNAAQEQFGGNPFASVGSSSSSGEGTQPSRTENRDPLPNPWAPPPATQSSATTSTTTSTGSGSGNSSSNATGNTVAAANYVASIFSTPGMQSLLQQITENPQLIQNMLSAPYMRSMMQSLSQNPDLAAQMMLNSPLFTANPQLQEQMRPQLPAFLQQMQNPDTLSAMSNPRAMQALMQIQQGLQTLATEAPGLIPSFTPGVGVGVLGTAIGPVGPVTPIGPIGPIVPFTPIGPIGPIGPTGPAAPPGSTGSGGPTGPTVSSAAPSETTSPTSESGPNQQFIQQMVQALAGANAPQLPNPEVRFQQQLEQLNAMGFLNREANLQALIATGGDINAAIERLLGSQPS | |
Overview of Protein Modification Sites with Functional and Structural Information | ||
* ASA = Accessible Surface Area
Locations | Modification | Substrate Peptides & Secondary Structure |
ASA (%) | Reference | Orthologous Protein Cluster |
---|---|---|---|---|---|
2 | Acetylation | ------MAENGESSG ------CCCCCCCCC | 20.97 | 22814378 | |
8 | Phosphorylation | MAENGESSGPPRPSR CCCCCCCCCCCCCCC | 51.52 | 24719451 | |
23 | Phosphorylation | GPAAAQGSAAAPAEP CCCHHCCCCCCCCCC | 11.58 | 29978859 | |
31 | Acetylation | AAAPAEPKIIKVTVK CCCCCCCCEEEEEEC | 48.87 | 23236377 | |
31 | Ubiquitination | AAAPAEPKIIKVTVK CCCCCCCCEEEEEEC | 48.87 | 22817900 | |
34 | Ubiquitination | PAEPKIIKVTVKTPK CCCCCEEEEEECCCC | 35.01 | 22817900 | |
36 | Phosphorylation | EPKIIKVTVKTPKEK CCCEEEEEECCCCHH | 15.98 | 29083192 | |
38 | Ubiquitination | KIIKVTVKTPKEKEE CEEEEEECCCCHHHC | 50.14 | 23000965 | |
39 | Phosphorylation | IIKVTVKTPKEKEEF EEEEEECCCCHHHCC | 34.94 | 20068231 | |
41 | Ubiquitination | KVTVKTPKEKEEFAV EEEECCCCHHHCCCC | 83.25 | 23000965 | |
43 | Ubiquitination | TVKTPKEKEEFAVPE EECCCCHHHCCCCCC | 69.53 | 23000965 | |
43 | Acetylation | TVKTPKEKEEFAVPE EECCCCHHHCCCCCC | 69.53 | 23236377 | |
58 | Ubiquitination | NSSVQQFKEAISKRF CCHHHHHHHHHHHHH | 41.73 | 23000965 | |
62 | Phosphorylation | QQFKEAISKRFKSQT HHHHHHHHHHHHHHH | 25.48 | 22210691 | |
63 | Ubiquitination | QFKEAISKRFKSQTD HHHHHHHHHHHHHHH | 56.60 | 23000965 | |
66 | Ubiquitination | EAISKRFKSQTDQLV HHHHHHHHHHHHHEE | 45.76 | 23000965 | |
67 | Phosphorylation | AISKRFKSQTDQLVL HHHHHHHHHHHHEEE | 35.28 | 21712546 | |
69 | Phosphorylation | SKRFKSQTDQLVLIF HHHHHHHHHHEEEEE | 32.57 | 22210691 | |
79 | Ubiquitination | LVLIFAGKILKDQDT EEEEEECHHHCCCCH | 41.24 | 23000965 | |
82 | Ubiquitination | IFAGKILKDQDTLIQ EEECHHHCCCCHHHH | 57.74 | 23000965 | |
104 | O-linked_Glycosylation | TVHLVIKSQNRPQGQ EEEEEEECCCCCCCC | 22.89 | 30059200 | |
112 | Phosphorylation | QNRPQGQSTQPSNAA CCCCCCCCCCCCCCC | 35.52 | 27732954 | |
112 | O-linked_Glycosylation | QNRPQGQSTQPSNAA CCCCCCCCCCCCCCC | 35.52 | 30059200 | |
113 | Phosphorylation | NRPQGQSTQPSNAAG CCCCCCCCCCCCCCC | 36.29 | 27732954 | |
113 | O-linked_Glycosylation | NRPQGQSTQPSNAAG CCCCCCCCCCCCCCC | 36.29 | 30059200 | |
116 | O-linked_Glycosylation | QGQSTQPSNAAGTNT CCCCCCCCCCCCCCC | 29.32 | 30059200 | |
116 | Phosphorylation | QGQSTQPSNAAGTNT CCCCCCCCCCCCCCC | 29.32 | 27732954 | |
121 | O-linked_Glycosylation | QPSNAAGTNTTSAST CCCCCCCCCCCCCCC | 25.35 | 30059200 | |
121 | Phosphorylation | QPSNAAGTNTTSAST CCCCCCCCCCCCCCC | 25.35 | 23186163 | |
123 | O-linked_Glycosylation | SNAAGTNTTSASTPR CCCCCCCCCCCCCCC | 23.20 | 30059200 | |
123 | Phosphorylation | SNAAGTNTTSASTPR CCCCCCCCCCCCCCC | 23.20 | 29116813 | |
124 | O-linked_Glycosylation | NAAGTNTTSASTPRS CCCCCCCCCCCCCCC | 25.10 | 30059200 | |
124 | Phosphorylation | NAAGTNTTSASTPRS CCCCCCCCCCCCCCC | 25.10 | 21955146 | |
125 | O-linked_Glycosylation | AAGTNTTSASTPRSN CCCCCCCCCCCCCCC | 20.41 | 30059200 | |
125 | Phosphorylation | AAGTNTTSASTPRSN CCCCCCCCCCCCCCC | 20.41 | 28985074 | |
127 | O-linked_Glycosylation | GTNTTSASTPRSNST CCCCCCCCCCCCCCC | 38.42 | 30059200 | |
127 | Phosphorylation | GTNTTSASTPRSNST CCCCCCCCCCCCCCC | 38.42 | 21955146 | |
128 | O-linked_Glycosylation | TNTTSASTPRSNSTP CCCCCCCCCCCCCCC | 23.57 | 30059200 | |
128 | Phosphorylation | TNTTSASTPRSNSTP CCCCCCCCCCCCCCC | 23.57 | 21955146 | |
206 | Sulfoxidation | DLMRQLIMANPQMQQ HHHHHHHHHCHHHHH | 3.92 | 28183972 | |
211 | Sulfoxidation | LIMANPQMQQLIQRN HHHHCHHHHHHHHHC | 2.64 | 28183972 | |
222 | Phosphorylation | IQRNPEISHLLNNPD HHHCHHHHHHHCCHH | 13.35 | - | |
249 | Methylation | AMMQEMMRNQDLALS HHHHHHHHCCCHHHH | 36.03 | - | |
256 | Phosphorylation | RNQDLALSNLESIPG HCCCHHHHCHHCCCC | 33.49 | 27050516 | |
260 | Phosphorylation | LALSNLESIPGGYNA HHHHCHHCCCCHHHH | 36.93 | 28152594 | |
265 | Phosphorylation | LESIPGGYNALRRMY HHCCCCHHHHHHHHH | 11.81 | 28152594 | |
269 | Methylation | PGGYNALRRMYTDIQ CCHHHHHHHHHHHCH | 20.93 | - | |
272 | Phosphorylation | YNALRRMYTDIQEPM HHHHHHHHHHCHHHH | 10.23 | 24043423 | |
273 | Phosphorylation | NALRRMYTDIQEPML HHHHHHHHHCHHHHH | 19.79 | 24043423 | |
294 | Phosphorylation | FGGNPFASVGSSSSS HCCCCCCCCCCCCCC | 27.65 | 24043423 | |
297 | Phosphorylation | NPFASVGSSSSSGEG CCCCCCCCCCCCCCC | 25.54 | 22210691 | |
298 | Phosphorylation | PFASVGSSSSSGEGT CCCCCCCCCCCCCCC | 28.45 | 24043423 | |
299 | Phosphorylation | FASVGSSSSSGEGTQ CCCCCCCCCCCCCCC | 30.16 | 24043423 | |
300 | Phosphorylation | ASVGSSSSSGEGTQP CCCCCCCCCCCCCCC | 44.29 | 24043423 | |
301 | Phosphorylation | SVGSSSSSGEGTQPS CCCCCCCCCCCCCCC | 42.69 | 24043423 | |
305 | Phosphorylation | SSSSGEGTQPSRTEN CCCCCCCCCCCCCCC | 32.76 | 22210691 | |
308 | Phosphorylation | SGEGTQPSRTENRDP CCCCCCCCCCCCCCC | 41.85 | 22210691 | |
508 | O-linked_Glycosylation | IGPIVPFTPIGPIGP CCCCCCCCCCCCCCC | 14.13 | 30059200 | |
519 | O-linked_Glycosylation | PIGPIGPTGPAAPPG CCCCCCCCCCCCCCC | 51.05 | 30059200 | |
527 | O-linked_Glycosylation | GPAAPPGSTGSGGPT CCCCCCCCCCCCCCC | 35.06 | 30059200 | |
528 | O-linked_Glycosylation | PAAPPGSTGSGGPTG CCCCCCCCCCCCCCC | 41.08 | 30059200 | |
530 | O-linked_Glycosylation | APPGSTGSGGPTGPT CCCCCCCCCCCCCCC | 40.44 | 30059200 | |
539 | O-linked_Glycosylation | GPTGPTVSSAAPSET CCCCCCCCCCCCCCC | 19.41 | 30059200 | |
546 | O-linked_Glycosylation | SSAAPSETTSPTSES CCCCCCCCCCCCCCC | 36.59 | 30059200 | |
550 | O-linked_Glycosylation | PSETTSPTSESGPNQ CCCCCCCCCCCCCCH | 44.91 | 30059200 | |
551 | O-linked_Glycosylation | SETTSPTSESGPNQQ CCCCCCCCCCCCCHH | 32.90 | 30059200 | |
553 | O-linked_Glycosylation | TTSPTSESGPNQQFI CCCCCCCCCCCHHHH | 60.36 | 30059200 | |
621 | Phosphorylation | AIERLLGSQPS---- HHHHHHCCCCC---- | 38.60 | 28985074 |
Modified Location | Modified Residue | Modification | Function | Reference | ||
---|---|---|---|---|---|---|
Oops, there are no descriptions of PTM sites of UBQL2_HUMAN !! |
* Distance = the distance between SAP position and PTM sites.
Modified Location | Modification | Variant Position (Distance <= 10) |
Residue Change | SAP | Related Disease | Reference |
---|---|---|---|---|---|---|
Oops, there are no SNP-PTM records of UBQL2_HUMAN !! |
Kegg Disease | ||||||
---|---|---|---|---|---|---|
There are no disease associations of PTM sites. | ||||||
OMIM Disease | ||||||
300857 | Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia (ALS15) | |||||
Kegg Drug | ||||||
There are no disease associations of PTM sites. | ||||||
DrugBank | ||||||
There are no disease associations of PTM sites. |
loading...
Acetylation | |
Reference | PubMed |
"Lys-N and trypsin cover complementary parts of the phosphoproteome ina refined SCX-based approach."; Gauci S., Helbig A.O., Slijper M., Krijgsveld J., Heck A.J.,Mohammed S.; Anal. Chem. 81:4493-4501(2009). Cited for: ACETYLATION [LARGE SCALE ANALYSIS] AT ALA-2, AND MASS SPECTROMETRY. |